See other companies on Welcome to the Jungle
DNA Script
Innovations in DNA synthesis for biological development
- 201-500 employees
- B2B
- Biology
- Science
- MedTech
- Le Kremlin-Bicêtre, France
Jump to section
Company mission
To accelerate breakthroughs in life science and human health.
14% employee growth in 12 months
Our take
Outsourcing DNA synthesis can be a large problem for R&D labs, as unprecedented factors such as delivery delays or issues on arrival can lead to schedule alterations and material that is no longer suitable for use. DNA Script attempts to solve this issue by democratising DNA synthesis for laboratories everywhere.
DNA Script facilitates biological and scientific development through providing proprietary equipment to labs that facilitates in-house DNA synthesis. The equipment eliminates the need for a reliance on external sources, and can significantly speed up workflows and operational efficiencies.
An issue found with equipment is that the DNA synthesised may vary in quality across locations, a problem that the company is committed to addressing through investigations and evaluation. By increasing the ability of labs to carry out DNA synthesis, the possibilities of the tech are vast and have the potential for significant revolutionary scientific developments. 2022 funding has facilitated the advance of DNA Script's SYNTAX Platform, allowing scientists to print synthetic nucleic acids, avoiding the need for third-party waiting times.
Steph
Company Specialist at Welcome to the Jungle
Company values
- Excellence: Take responsibility for your work. Aim to act, do, and behave with the goal of reaching the unreachable
- Transparency: Give sincere, reliable, and trustworthy information. Bring objective facts, no matter how they look
- Benevolence: Create a positive environment for everyone. Be supportive to the team, the company, and your colleagues
Funding (last 2 of 8 rounds)
Jan 2022
$35m
SERIES C
Oct 2021
$165m
SERIES C
Total funding: $311m
This company has top investors
Leadership
Thomas Ybert
(CEO & Board Director)Previously a Metabolic Engineering Project Leader at Amyris and a Biotechnological Senior Scientist at TOTAL.
Xavier Godron
(CTO)Previously an Analyst at TOTAL and an Engineer at Akuo Energy.
Sylvain Gariel
(COO)Previously a Research Analyst at TOTAL, a Business Analyst at URGO, and a Mining Engineer for the French Ministry of Industry. Also worked as a Portfolio Manager for a state shareholding agency.